In a retrospective study of 121 EGFR mutant NSCLC patients with gradual progression following first-line EGFR TKI, the addition of anlotinib extended the median PFS by 3 months over EGFR TKI alone (6.7 vs. 3.6 months, P < 0.001) (Xiang et al., 2024). Here, EGFR is linked to non-small cell lung carcinoma.